EFFECTIVE Act

This bill (S 607, the EFFECTIVE Act) requires the FDA to deny approval for new opioid painkiller drugs unless they demonstrate a significant safety or effectiveness advantage over existing comparable drugs. It directly affects pharmaceutical companies seeking to market new opioid analgesics by adding a new standard to the drug approval process. The key provision amends the Federal Food, Drug, and Cosmetic Act to give the FDA Secretary authority to reject opioid drug applications that don't meet this "significant advantage" threshold. This policy change aims to ensure new opioid medications offer meaningful benefits before reaching patients.